Statistical analyses

- OS: Overall survival
- PFS: Progression-free survival
- ORR: Objective response rate
- SUA: Secondary use analyses
- GEE: Generalized estimating equation
- PROs: Patient-reported outcomes
- VAS: Visual analogue scale

RESULTS

- PRO scores showed improvement with ripretinib compared to placebo.
- The highest common terminology criteria for adverse events (CTCAE) severity categories, n (%)

Table 2. Tables in-50% of patients receiving ripretinib

Table 3. Patients with alopecia and PPES

Table 4. Graded TEAEs for alopecia and PPES

Figure 1. INVICTUS study design

Figure 2. Median first appearance and worst grade of alopecia and PPES in the ripretinib arm

Figure 3. Mean change from baseline in overall health (A) and overall quality of life (B) in patients receiving ripretinib with and without alopecia

Figure 4. Mean change from baseline in state of health (A) and social function (B) in patients receiving ripretinib with and without alopecia

Figure 5. Mean change from baseline in state of health (A) and social function (B) in patients receiving ripretinib with and without alopecia

CONCLUSIONS

- Ripretinib demonstrated a significant improvement in median progression-free survival (PFS) vs placebo in patients with GIST, both with and without PPES, and a clinically meaningful median overall survival in patients 54.1 months in the ripretinib arm and 20.4 months in the placebo arm.
- The incidence of alopecia was similar in patients receiving ripretinib with and without PPES.
- Anemia was the most common grade 3/4 TEAE (9.4%) in the ripretinib arm; grade 3/4 neutropenia was 4.2% in the ripretinib arm and 2.6% in the placebo arm.
- The majority of patients (61%) who developed PPES were treated with ripretinib.
- Patients with alopecia or PPES had a lower PRO score compared to those without alopecia or PPES.
- In patients receiving ripretinib, the median time to first appearance of alopecia and the median time to worst grade of alopecia were 115.39 months in the ripretinib arm and 7.39 months in the placebo arm. The median time to first appearance of PPES was 0 months in both arms (Figure 2).

Abstract: 11539
Poster: 427

Presented at the 2020 ASCO Annual Virtual Meeting
May 30–31, 2020

Alopecia was the most common grade 3/4 TEAE (9.4%) in the ripretinib arm; grade 3/4 neutropenia was 4.2% in the ripretinib arm and 2.6% in the placebo arm.

The majority of patients (61%) who developed PPES were treated with ripretinib.

Patients with alopecia or PPES had a lower PRO score compared to those without alopecia or PPES.

In patients receiving ripretinib, the median time to first appearance of alopecia and the median time to worst grade of alopecia were 115.39 months in the ripretinib arm and 7.39 months in the placebo arm. The median time to first appearance of PPES was 0 months in both arms (Figure 2).

Abstract: 11539
Poster: 427

Presented at the 2020 ASCO Annual Virtual Meeting
May 30–31, 2020

Alopecia was the most common grade 3/4 TEAE (9.4%) in the ripretinib arm; grade 3/4 neutropenia was 4.2% in the ripretinib arm and 2.6% in the placebo arm.

The majority of patients (61%) who developed PPES were treated with ripretinib.

Patients with alopecia or PPES had a lower PRO score compared to those without alopecia or PPES.

In patients receiving ripretinib, the median time to first appearance of alopecia and the median time to worst grade of alopecia were 115.39 months in the ripretinib arm and 7.39 months in the placebo arm. The median time to first appearance of PPES was 0 months in both arms (Figure 2).

Abstract: 11539
Poster: 427

Presented at the 2020 ASCO Annual Virtual Meeting
May 30–31, 2020

Alopecia was the most common grade 3/4 TEAE (9.4%) in the ripretinib arm; grade 3/4 neutropenia was 4.2% in the ripretinib arm and 2.6% in the placebo arm.

The majority of patients (61%) who developed PPES were treated with ripretinib.

Patients with alopecia or PPES had a lower PRO score compared to those without alopecia or PPES.

In patients receiving ripretinib, the median time to first appearance of alopecia and the median time to worst grade of alopecia were 115.39 months in the ripretinib arm and 7.39 months in the placebo arm. The median time to first appearance of PPES was 0 months in both arms (Figure 2).